KZR

Kezar Life Sciences Inc

Add to Watchlist

Advanced Chart

4.310

-0.16(-3.579%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.580

Open

4.450

VWAP

4.45

Vol

53.18K

Mkt Cap

31.49M

Low

4.2701

Amount

236.40K

EV/EBITDA(TTM)

Total Shares

72.80M

-73.78M

EV/OCF(TTM)

P/S(TTM)

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-2.324

-15.63%

-2.086

-24.96%

-1.804

-39.87%

Estimates Revision

The market is revising No Change the revenue expectations for Kezar Life Sciences, Inc. (KZR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -0.46%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-1.88%

In Past 3 Month

Stock Price

Go Down

-0.46%

In Past 3 Month

3 Analyst Rating

62.41% Upside

Wall Street analysts forecast KZR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KZR is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

62.41% Upside

Current: 4.310

Low

7.00

Averages

7.00

High

7.00

62.41% Upside

Current: 4.310

Low

7.00

Averages

7.00

High

7.00

Wells Fargo

Derek Archila

Hold

Maintains

$11 → $9

2024-12-19

Reason

Wells Fargo

Derek Archila

Price Target

$11 → $9

2024-12-19

Maintains

Hold

Reason

Wells Fargo analyst Derek Archila lowered the firm's price target on Kezar Life Sciences to $9 from $11 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).

HC Wainwright & Co.

Raghuram Selvaraju

Hold

Reiterates

n/a

2024-12-02

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

n/a

2024-12-02

Reiterates

Hold

Reason

Wells Fargo

Derek Archila

Hold

Maintains

$20 → $11

2024-11-14

Reason

Wells Fargo

Derek Archila

Price Target

$20 → $11

2024-11-14

Maintains

Hold

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Hold

Reiterates

n/a

2024-10-18

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

n/a

2024-10-18

Reiterates

Hold

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Hold

Reiterates

n/a

2024-10-14

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

n/a

2024-10-14

Reiterates

Hold

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Hold

Downgrades

n/a

2024-10-02

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

n/a

2024-10-02

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Kezar Life Sciences Inc (KZR.O) is -0.58, compared to its 5-year average forward P/E of -4.12. For a more detailed relative valuation and DCF analysis to assess Kezar Life Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.12

Current PE

-0.58

Overvalued PE

-0.43

Undervalued PE

-7.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

8.26

Current PS

0.00

Overvalued PS

24.08

Undervalued PS

-7.55

Financials

Annual

Quarterly

FY2025Q1

N/A

Total Revenue

FY2025Q1

YoY :

-25.65%

-17.63M

Operating Profit

FY2025Q1

YoY :

-23.56%

-16.56M

Net Income after Tax

FY2025Q1

YoY :

-23.83%

-2.27

EPS - Diluted

FY2025Q1

YoY :

-24.77%

-17.20M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.5K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.5K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

KZR News & Events

Events Timeline

2025-07-15 (ET)

2025-07-15

16:43:02

Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial

2025-05-13 (ET)

2025-05-13

16:02:53

Kezar Life Sciences reports Q1 EPS ($2.27), consensus ($2.65)

2025-03-25 (ET)

2025-03-25

07:49:15

Kezar Life Sciences reports topline results from PORTOLA trial

News

9.0

07-16Benzinga

FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study

9.0

07-16NASDAQ.COM

Kezar : FDA Lifts Partial Clinical Hold On Phase 2a Trial Of Zetomipzomib In Autoimmune Hepatitis

9.0

07-15Newsfilter

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis